Fractyl Health reports durable weight maintenance one year post-GLP-1
Fractyl Health reported positive one-year results from the REMAIN-1 Midpoint Cohort, showing its Revita DMR system reduced weight regain by 40% compared to sham procedures. Patients with complete duodenal ablation maintained 81% of weight loss, with a 91% responder rate and no serious adverse events.
*this image is generated using AI for illustrative purposes only.
Fractyl Health announced positive one-year results from its REMAIN-1 Midpoint Cohort, demonstrating that its Revita DMR system significantly reduced weight regain compared to sham procedures. In the full modified intention-to-treat (mITT) population (N=45), a single Revita procedure reduced weight regain by approximately 40% versus sham at one year. The least-squares mean weight regain was 7.8% versus 13.0% of body weight for Revita versus sham (n=29 versus 16).
Participants who received complete duodenal ablation (>14 cm) maintained approximately 81% of GLP-1-induced weight loss at one year, compared with 48% in sham participants. This group showed a least-squares mean weight regain of 4.8% versus 13.0% of body weight (n=17 versus 16 for Revita versus sham), reflecting a reduction in weight regain of over 60% versus sham. The data indicates that more complete duodenal ablation drives a greater treatment effect.
Optimized Population Results
In an optimized population of participants who received complete duodenal ablation (>14 cm) and had higher GLP-1 run-in weight loss (≥17.5%), Revita maintained approximately 84% of GLP-1-induced weight loss at one year versus 46% with sham. The least-squares mean weight regain was 4.1% versus 13.5% of body weight (n=10 versus 8 for Revita versus sham). These results suggest that patients at greatest need may derive the greatest benefit from Revita due to their higher propensity for weight regain after GLP-1 discontinuation.
Responder Rates and Safety
The weight-maintenance responder rate, a co-primary endpoint of the Pivotal Cohort, was 73% in the Midpoint Cohort mITT population. This rate rose to 91% in those with complete duodenal ablation (>14 cm). The endpoint measures the proportion of Revita patients maintaining at least 5% total body weight loss relative to their pre-tirzepatide weight at one year.
| Population | Weight Maintenance Responder Rate |
|---|---|
| Midpoint Cohort mITT | 73% |
| Complete duodenal ablation (>14 cm) | 91% |
Safety data indicated no device- or procedure-related serious adverse events occurred. No new device-related treatment-emergent adverse events (TEAEs) were observed between six and 12 months. Overall TEAE rates were comparable between arms through one year (24% Revita versus 25% sham). One new diagnosis of type 2 diabetes occurred in the sham arm versus none with Revita.
How will these positive one-year results influence the timeline for regulatory approval and potential commercial launch of the Revita DMR system?
What strategies might Fractyl Health employ to position Revita as a complementary therapy alongside GLP-1 agonists in the competitive weight management market?
Could the strong safety profile and high responder rates in the optimized population lead to broader insurance coverage for the procedure?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
